BriaCell Therapeutics Warrant
BCTXL
15 hedge funds and large institutions have $3.7M invested in BriaCell Therapeutics Warrant in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
127.95% more ownership
Funds ownership: 0% → 127.95% (+128%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.11M |
| 2 |
AC
Armistice Capital
New York
|
+$568K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$403K |
| 4 |
CCC
Cable Car Capital
San Francisco,
California
|
+$341K |
| 5 |
EAM
Empery Asset Management
New York
|
+$318K |
Top Sellers
BCTXL Hedge Fund Activity: Q1 2026 in Review
15 of the 8,197 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Warrant (BCTXL) for Q1 2026, worth a combined $3.7M.
Buyers outnumbered sellers: 15 funds opened new BCTXL positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $1.11M.
- 15 institutional investors held BriaCell Therapeutics Warrant (BCTXL) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $3.7M of BriaCell Therapeutics Warrant stock for Q1 2026.
- 15 funds opened new BriaCell Therapeutics Warrant positions in Q1 2026 and 0 closed out, a net change of +15 holders.
- The largest BriaCell Therapeutics Warrant buyer in Q1 2026 was Citadel Advisors, an estimated $1.11M added.
Based on aggregated 13F filings for Q1 2026.